Phase I/II Study of Spartalizumab (PDR001), An Anti-PD1 Mab, in Patients with Advanced Melanoma or Non-Small Cell Lung Cancer

Lin, C-C.Taylor, M.Boni, V.Brunsvig, P. F.Geater, S. L.Salvagni, S.Garrido Lopez, P.Ozguroglu, M.Sriuranpong, V.Ponce Aix, S.Ascierto, P. A.Fasolo, A.Sezer, A.Kowalski, D. M.Faris, J. E.Cameron, S.Mataraza, J.Wu, H.Antona, V.Ochoa de Olza, M.2023-04-182023-04-1820180923-7534http://hdl.handle.net/11727/8821enginfo:eu-repo/semantics/closedAccessPhase I/II Study of Spartalizumab (PDR001), An Anti-PD1 Mab, in Patients with Advanced Melanoma or Non-Small Cell Lung CancerConference Object29Supplement 8413413000459277302338